• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Basic study on prevention and treatment of type 1 diabetes mellitus with biological respomse modifiers.

Research Project

Project/Area Number 61570536
Research Category

Grant-in-Aid for General Scientific Research (C)

Allocation TypeSingle-year Grants
Research Field 内分泌・代謝学
Research InstitutionTOHOKU UNIVERSITY

Principal Investigator

SATOH Jo  Tohoku University Hospital, Tohoku University School of Medicine, 医学部付属病院, 助手 (60125565)

Co-Investigator(Kenkyū-buntansha) SHINTANI Shigeki  Tohoku University Hospital, Tohoku University school of Medicine, 医学部付属病院, 医員
TOYOTA Takayoshi  Tohoku University School of Medicine, 医学部, 助教授 (40003628)
下瀬川 徹  東北大学, 医学部附属病院, 医員
清水 文雄  東北大学, 歯学部, 助手 (10162710)
Project Period (FY) 1986 – 1987
Project Status Completed (Fiscal Year 1987)
Budget Amount *help
¥2,100,000 (Direct Cost: ¥2,100,000)
Fiscal Year 1987: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 1986: ¥1,300,000 (Direct Cost: ¥1,300,000)
Keywordstype 1 diabetes mellitus / IDDM / BRMs / OK-432 / NOD mouse / BB rat / 糖尿病の免疫療法 / 【I】型糖尿病 / インスリン依存型糖尿病 / 免疫修飾剤
Research Abstract

We previously reported that a streptococcal preparation (OK-432), one of BRMs, inhibited insulitis and prevented insulin-dependent (type 1) diabetes mellitus (IDDM) in NOD mice. In this project, we extended our previous observation to two studies; 1) effect of OK-432 on IDDM in BB rats as an another model of IDDM and 2) analysis of mechanisms of OK-432-action by usingNOD mice. The results and conslusions are as follows.
1)The cumulative incidence of diabetes was 27.7% (13/47) by 30 weeks of age in BB rats, whereas that was significantly suppressed in the rats (7.4%, 4/54, p<0.01) who were weekly and intraperitoneally treated with 0.2 mg of OK-432. Histological examinations revealed that the OK-432-treated BB rats retained a greater number of intact islets without lymphocytic infiltrations than did thenon-treated rats. The cytotoxic activities of spleen cells directed against a rat insulinoma cell line, RIN, were significantly suppressed in the OK-432-treated BB rats as compared with tho … More se in the non-treated rats, Thus, the OK-432 treatment suppressed insulitis and inhibited development of diabetes not only in NOD mice but also in BB rats.
2) Approximately 85% of the non-treated NOD mice developed diabetes by 25 weeks of age. On the other hand, the weekly injection (ip or iv) of 0.1mg of OK-432 from 4 or 5 to 15 ro 20 weeks of age completely inhibited development of diabetes and these NOD mice did not develop diabetes even after ceasing the OK-432-treatment. Cyclophosphamide enhanced the development of diabetes in thenon-treated NOD mice but not in the OK-432-treated mice. The diabetes wastransfered by the spleen cells from the non-treated NOD mice but not by the cells from the OK-432-treated mice. In addition, the spleen cells from the OK-432-treated mice inhibited the development of diabetes in the cyclophosphamide-treated mice and this inhibitory effect was eliminated by the treatment of cells with anti-Thy-1 antibody and complement. These indicate that the OK-432-treatment inhibited the induction of cytotoxic effector cells directed against pancreatic B cells and this effect was mediated by suppressor T cells. Less

Report

(2 results)
  • 1987 Final Research Report Summary
  • 1986 Annual Research Report
  • Research Products

    (12 results)

All Other

All Publications (12 results)

  • [Publications] 佐藤譲 他: 臨床免疫. 18(12). 1087-1094 (1986)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1987 Final Research Report Summary
  • [Publications] To Satoh et al.: Diabetes. (1988)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1987 Final Research Report Summary
  • [Publications] 後藤由夫,佐藤譲他編: "糖尿病動物1・OK-432によるBBラット糖尿病発症の抑制" 医療ジャーナル社, 101-107 (1987)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1987 Final Research Report Summary
  • [Publications] 後藤由夫,新谷茂樹他編: "糖尿病動物1・OK-432によるNODマウスの糖尿病発症抑制および発症後寛解誘導" 医療ジャーナル社, 94-100 (1987)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1987 Final Research Report Summary
  • [Publications] Jo Satoh et al.: "Treatment with a streptococcal preparation (OK-432) suppresses auti-islet autoimmunity and prevents diabetes." Diabetes. (1988)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1987 Final Research Report Summary
  • [Publications] Jo Satoh et al: "NOD/Sendai mice with high incidence of type 1 diabetes are not T lymphocytopenic" in submission.

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1987 Final Research Report Summary
  • [Publications] Shigeki Shintani: "Inhibition of type 1 diabetes in NOD mice by a streptococcal preparation (OK-432):" Mechanisms of action of OK-432.

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1987 Final Research Report Summary
  • [Publications] 新谷茂樹,他: 日本免疫学会総会・学術集会記録. 16. 678 (1986)

    • Related Report
      1986 Annual Research Report
  • [Publications] 佐藤譲,他: 日本内科学会雑誌. 76. 124 (1987)

    • Related Report
      1986 Annual Research Report
  • [Publications] Jo Satoh et al.: Diabetes.

    • Related Report
      1986 Annual Research Report
  • [Publications] 新谷茂樹,他: 糖尿病動物. (1987)

    • Related Report
      1986 Annual Research Report
  • [Publications] 佐藤譲,他: 糖尿病動物. (1987)

    • Related Report
      1986 Annual Research Report

URL: 

Published: 1987-03-31   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi